VXRT News and Press, Vaxart Inc. From 01/07/21

Moderna and Pfizer were first to market with their coronavirus vaccines. The U.S. Food and Drug Administration (FDA) granted them both Emergency Use Authorization (EUA) last month. But that doesn't mean the vaccine race is over. Considering global demand, there is plenty of room for...

Shares of Vaxart (NASDAQ: VXRT) tumbled 28.5% in December, according to data provided by S&P Global Market Intelligence , as investors continued to take stock of its oral COVID-19 vaccine. The biotech rocketed to stratospheric heights earlier in the year on the promise t...

Vaxart has been developing its oral COVID-19 vaccine since early January 2020 and I broadly agree analyst consensus price target of $17.70. The company has - surprisingly - few rivals in this space and the logic of developing an oral COVID-19 vaccine is sound. Easier distribution, cos...

Vaxart as a COVID-19 vaccine play had surged after upbeat news in June, but is now at lower valuations. Still, the stock price is on a net one-year uptrend, as a result of the biotech's quite unique treatment being developed against the coronavirus. Moreover, the company's image h...

Biotechvalley Insights is upgrading ALT's rating to "Very Bullish" from a "Bullish" rating with a 12 month TP of US$52. Altimmune's (ALT) valuation is at a discount after the recent sell-off, and the fundamental picture has improved with more clarity around manufacturing. ALT has ...

Is it a good idea to keep betting on a winner? That question may have crossed our minds as we look at Novavax (NASDAQ: NVAX) and Vaxart (NASDAQ: VXRT) . Shares of these coronavirus vaccine developers soared more than 3,000% and 2,000%, respectively, this year. That makes the...

The Premium Portfolio has gained +44.54% YTD compared to the S&P 500 +14.81% YTD beating the index by +29.7% with one week to go. The Premium Portfolio has beaten the S&P 500 every year since inception with 32% avg annual returns from 20.8% in 2018, 30.7% in 2019. Weekly r...

GoodRx Holdings (NASDAQ: GDRX) , Vaxart (NASDAQ: VXRT) , and Teladoc Health (NYSE: TDOC) are all up considerably for the year, but I'm concerned about where their share prices might be headed next year. All three companies have been able to thrive during the coronavi...

Many of the best stocks in 2020 were healthcare companies focused on two disease areas: trying to stop the spread of COVID-19 and improving survival rates from deadly diseases. Their scientific achievements have been nothing less than extraordinary. By looking at healthcare companies with m...

In the race to develop vaccines against COVID-19, various pharmaceutical and biotech companies have made use of a number of innovative methods. Messenger-RNA vaccines. Electroporation devices that deliver DNA plasmid vaccines directly into patients' cells. And, in the case of Vaxart (...